Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

BioNTech (BNTX) Stock Forecast & Price Target

BioNTech logo
$103.01 -1.78 (-1.70%)
Closing price 04:00 PM Eastern
Extended Trading
$103.45 +0.44 (+0.43%)
As of 05:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

BioNTech - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy
Based on 17 Analyst Ratings
Sell
0
Hold
4
Buy
13

Based on 17 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, and 13 have given a buy rating for BNTX.

Consensus Price Target

$135.80
31.83% Upside
According to the 17 analysts' twelve-month price targets for BioNTech, the average price target is $135.80. The highest price target for BNTX is $171.44, while the lowest price target for BNTX is $110.00. The average price target represents a forecasted upside of 31.83% from the current price of $103.01.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BNTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for BioNTech and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BNTX Analyst Ratings Over Time

TypeCurrent Forecast
8/27/24 to 8/27/25		1 Month Ago
7/28/24 to 7/28/25		3 Months Ago
5/29/24 to 5/29/25		1 Year Ago
8/28/23 to 8/27/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
14 Buy rating(s)
5 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
5 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$135.80$136.58$141.73$109.09
Forecasted Upside31.83% Upside21.09% Upside41.38% Upside25.23% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

BioNTech Stock vs. The Competition

TypeBioNTechMedical CompaniesS&P 500
Consensus Rating Score
2.76
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside32.91% Upside14,681.07% Upside10.12% Upside
News Sentiment Rating
Positive News

See Recent BNTX News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/14/2025HC Wainwright
1 of 5 stars		Robert Burns
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetBuy ➝ Buy$138.00 ➝ $136.00+21.57%
8/5/2025Bank of America
4 of 5 stars		Tazeen Ahmad
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$126.00 ➝ $134.00+21.78%
8/5/2025Wells Fargo & Company
3 of 5 stars		Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set TargetOverweight ➝ Overweight$170.00 ➝ $150.00+36.32%
7/10/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Terence Flynn
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$132.00 ➝ $133.00+18.45%
6/3/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Asthika Goonewardene
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$151.00 ➝ $155.00+33.39%
6/2/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Daina Graybosch
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Set Target$112.00+2.47%
5/29/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy ➝ Neutral$110.00+12.79%
5/22/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Jessica Fye
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower TargetNeutral ➝ Neutral$120.00 ➝ $116.00+17.24%
5/6/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		G. Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$145.00 ➝ $140.00+38.48%
3/11/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		John Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$171.44 ➝ $171.44+65.58%
3/11/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Etzer Darout
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$130.00 ➝ $143.00+35.74%
11/19/2024Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		H. Gillis
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated CoverageBuy$130.00+27.61%
11/19/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeIn-Line ➝ Outperform$110.00 ➝ $125.00+22.71%
11/5/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetHold ➝ Hold$132.00 ➝ $122.00+10.28%
10/7/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$97.00 ➝ $136.00+10.88%
9/19/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$95.00 ➝ $150.00+33.87%
9/18/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$97.00 ➝ $131.00+5.04%
9/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$96.00 ➝ $150.00+21.49%
8/2/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating		R. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Strong-Buy
1/5/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageMarket Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:18 PM ET.


Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 25, 2025. Please send any questions or comments about these BioNTech pros and cons to contact@marketbeat.com.

BioNTech
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in BioNTech SE:

  • The current stock price is around $110.88, which is positioned above its 52-week low, indicating potential for growth.
  • BioNTech SE has received a "buy" rating from multiple analysts, with a recent price target increase to $155.00, suggesting strong future performance expectations.
  • The company reported a significant year-over-year revenue increase of over 100%, showcasing its strong market position and growth potential.
  • Thirteen analysts have rated the stock as a "buy," reflecting positive sentiment and confidence in the company's future prospects.
  • BioNTech SE has a low debt-to-equity ratio, indicating financial stability and a lower risk profile for investors.

BioNTech
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in BioNTech SE for these reasons:

  • The company reported a negative earnings per share (EPS) of ($1.60), which missed consensus estimates, indicating potential challenges in profitability.
  • BioNTech SE has a negative return on equity, suggesting that the company is not currently generating profit relative to shareholder equity.
  • The stock has a high price-to-earnings (PE) ratio, which can indicate that the stock is overvalued compared to its earnings.
  • Market volatility is reflected in the stock's beta of 1.23, suggesting that it may be more volatile than the overall market, which could pose risks for investors.
  • Despite strong revenue growth, the company has a negative net margin, indicating that it is currently spending more than it earns, which could be a concern for long-term sustainability.

BNTX Forecast - Frequently Asked Questions

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $135.80, with a high forecast of $171.44 and a low forecast of $110.00.

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BNTX shares.

According to analysts, BioNTech's stock has a predicted upside of 31.83% based on their 12-month stock forecasts.

BioNTech has been rated by research analysts at Bank of America, HC Wainwright, Leerink Partners, Morgan Stanley, The Goldman Sachs Group, Truist Financial, and Wells Fargo & Company in the past 90 days.

Analysts like BioNTech less than other "medical" companies. The consensus rating score for BioNTech is 2.76 while the average consensus rating score for "medical" companies is 2.78. Learn more on how BNTX compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NASDAQ:BNTX) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...
Brownstone Research | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsoredtc pixel
This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...
Paradigm Press | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsoredtc pixel
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsoredtc pixel
Out of 18,347 Cryptocurrencies... This is the ONLY One
The Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...
Crypto 101 Media | Sponsoredtc pixel